CytoMed Therapeutics Limited (NASDAQ:GDTC – Get Free Report)’s stock price dropped 13.7% during trading on Tuesday . The company traded as low as $2.77 and last traded at $2.96. Approximately 313,428 shares traded hands during mid-day trading, a decline of 89% from the average daily volume of 2,783,089 shares. The stock had previously closed at $3.43.
Analyst Ratings Changes
Separately, Benchmark reaffirmed a “speculative buy” rating and set a $5.00 target price on shares of CytoMed Therapeutics in a report on Thursday, October 10th.
Check Out Our Latest Stock Analysis on CytoMed Therapeutics
CytoMed Therapeutics Price Performance
CytoMed Therapeutics Company Profile
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.
Further Reading
- Five stocks we like better than CytoMed Therapeutics
- CD Calculator: Certificate of Deposit Calculator
- Disney: Forging a 3-Headed Sports Streaming Giant With Fubo Deal
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- How Buffett’s Best and Worst Stock Bets Have Fared 5 Years Later
- Where to Find Earnings Call Transcripts
- Bill Ackman’s Bold Case for Fannie Mae and Freddie Mac
Receive News & Ratings for CytoMed Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoMed Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
